<DOC>
	<DOC>NCT00487682</DOC>
	<brief_summary>To investigate the efficacy and safety of three different doses of ASP2151, as compared to valacyclovir hydrochloride in subjects with herpes zoster, and to determine the recommended clinical dose.</brief_summary>
	<brief_title>Dose-finding Study of ASP2151 in Subjects With Herpes Zoster</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Subjects aged from 20 years to under 80 years on the day informed consent is obtained Subjects to whom the study drugs can be orally administered within 72 hours after the onset of rash due to herpes zoster Subjects in whom protocolspecified observations and assessments are considered possible Subjects with extremely compromised immune function due to underlying diseases, treatment with Immunosuppressive agents etc., or radiotherapy Subjects with a serious underlying disease that corresponds to Grade 3 in the Classification Criteria for teh Seriousness of Adverse Drug Reactions Subjects with concurrent malignant tumors, or those with a history of malignant tumors within the past 5 years</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>herpes zoster</keyword>
	<keyword>ASP2151</keyword>
	<keyword>Valacyclovir hydrochloride</keyword>
</DOC>